THURSDAY, Oct. 1, 2026 -- For adults with type 2 diabetes and moderate cardiovascular risk with albuminuria, glucagon-like peptide-1 (GLP-1) receptor agonists or sodium-glucose cotransporter-2 (SGLT-2) inhibitors reduce the risk for deterioration of...
| # | Наименование новости | Тональность | Информативность | Дата публикации |
|---|---|---|---|---|
| 1 | EADV: Nail Disorders Occur Frequently With GLP-1 Receptor Agonist Exposure | 0 | 11.22 | 07-10-2026 |
| 2 | Empagliflozin and the Risk of Retinopathy in Type 2 Diabetes | 0 | 11.22 | 01-01-2025 |
| 3 | AA: Pulmonary Aspiration, Regurgitation Under Anesthesia More Likely With GLP-1 RAs | 0 | 15.63 | 02-10-2026 |
| 4 | Descartan que usar Ozempic influya en el riesgo de enfermedad ocular degenerativa | 0 | 7.65 | 17-08-2026 |
| 5 | A ‘living GLP-1 drug’ could revolutionize diabetes treatment | 0 | 12.36 | 20-08-2026 |
| 6 | EASD: Combined Intervention in Early-Onset Type 2 Diabetes Tied to High Remission Rates | 0 | 17.94 | 06-10-2026 |
| 7 | Un medicamento para la diabetes previene enfermedades del corazón | 0 | 8.34 | 29-06-2026 |
| 8 | Обнаружен новый побочный эффект от уколов для похудения | 0 | 9.22 | 02-10-2026 |
| 9 | Минздрав связал рост заболеваемости диабетом II типа с неправильным питанием | 1 | 6.77 | 02-10-2026 |
| 10 | EASD: Neurodiversity Prevalence Elevated for Those With Early Diagnosis of Type 2 Diabetes | 0 | 10.14 | 01-10-2026 |